Scholar Rock Holding Corporation (SRRK) analyst actions
Rating and price-target actions on SRRK in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SRRK overview →
1 measured SRRK analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity | Press release | -0.16% | -3.94% |
Keep exploring
More SRRK: earnings → · SEC filings → · SRRK overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 426 | -0.21% | 43% |
| Summit Therapeutics Inc. (SMMT) | 426 | +0.03% | 50% |
| Koninklijke Philips N.V. NY Registry Shares (PHG) | 424 | +0.04% | 53% |
| Waters Corporation (WAT) | 424 | +0.05% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.